Sermorelin Clinical Evidence: Efficacy and Safety
Sermorelin has limited but positive clinical evidence for treating pediatric growth hormone deficiency, showing sustained increases in height velocity during 12 months of treatment, though it is not FDA-approved and has been largely superseded by recombinant human growth hormone (rhGH) in clinical practice.
Critical Context: Sermorelin vs. Standard Treatment
The provided FDA drug labels 1 are for sertraline (an antidepressant), not sermorelin. This appears to be a database error. Current clinical guidelines 2, 3 focus exclusively on recombinant human growth hormone (rhGH) as the standard treatment for GHD, with FDA approval since 1985 3. Sermorelin is not mentioned in modern treatment guidelines, indicating it is not part of standard clinical practice.
Efficacy Evidence
Pediatric Growth Hormone Deficiency
Diagnostic Use:
- Intravenous sermorelin 1 μg/kg bodyweight provides a rapid, relatively specific test for GHD diagnosis 4
- Critical limitation: Normal GH responses to sermorelin cannot exclude hypothalamic GHD; subnormal responses to other provocative tests are needed for confirmation 4
- Fewer false positives compared to other provocative tests 4
Treatment Efficacy:
- Dosing: Subcutaneous sermorelin 30 μg/kg bodyweight once daily at bedtime 4, 5
- Height velocity response: Increased from baseline 4.1 ± 0.9 cm/year to 8.0 ± 1.5 cm/year at 6 months and 7.2 ± 1.3 cm/year at 12 months 5
- Response rate: 74% of children showed good response at 6 months 5
- Sustained effect: Limited data suggest effects maintained for up to 36 months 4
- Bone age progression: Ratio of bone age change to height age change was 1.04 ± 0.58 at 12 months (not significantly different from unity), indicating appropriate skeletal maturation 5
Comparative Effectiveness
Sermorelin is inferior to rhGH: Height velocity increases with subcutaneous sermorelin 30 μg/kg/day (given as continuous infusion or 3 divided doses) were less than those achieved with once-daily subcutaneous rhGH 30 μg/kg/day 4. This is a critical finding that explains why sermorelin is not used in modern practice.
Idiopathic Short Stature (Non-GHD)
In children with idiopathic short stature (peak GH >20 mU/L on testing):
- Sermorelin 20 μg/kg twice daily increased height velocity from 4.8 ± 0.9 cm/year to 7.2 ± 1.6 cm/year at 12 months 6
- Catch-down growth occurred: After cessation, height velocity dropped to 3.89 ± 1.82 cm/year in first 3 months, returning to baseline by 12 months 6
- Final height prediction increased by only 3.4 ± 2.6 cm 6
Predictors of Response
- Slower growing children at baseline
- Shorter stature
- Delayed bone age and height age
- Pretreatment peak GH response >30 mU/L during IV GHRH test (though lower peaks don't preclude response)
Safety Profile
Adverse Events
- Most common: Transient facial flushing and injection site pain
- No adverse changes in general biochemical or hormonal analyses 5
- No excessive IGF-I generation 5
- No change in fasting glucose concentration during treatment 5
Metabolic effects in idiopathic short stature 6:
- Fasting blood glucose and insulin levels increased during therapy
- IGF-I levels increased
- Overnight GH levels and GH responses to GHRH testing fell during 12 months of therapy
Antibody Development
Anti-GHRH antibodies developed in 14 of 18 patients in one study 7, but these did not appear to have adverse effects on either growth or GH responses to GHRH 7.
Critical Limitations
No data on final adult height: The effect of long-term sermorelin treatment on final adult height has not been determined 4
Inferior to standard therapy: Direct comparisons show rhGH produces superior height velocity increases 4
Not in current guidelines: Modern GHD treatment guidelines 2, 3, 8 do not include sermorelin as a treatment option
Limited long-term data: Most studies are 12 months or less, with only anecdotal data to 36 months 4
Hypothalamic GHD may be missed: Normal sermorelin response doesn't exclude GHD due to hypothalamic dysfunction 4
Clinical Practice Reality
Recombinant human GH is the standard of care 2, 3, 8:
- FDA-approved since 1985 for pediatric GHD 3
- Dosing: 25-50 μg/kg/day in the US, up to 100 μg/kg/day in puberty 2
- Long-acting GH preparations approved in 2021 2
- Extensive long-term safety data from 15,809 patients showing overall safety profile 9
Sermorelin has no role in modern clinical practice for GHD treatment, having been replaced by more effective rhGH therapy with better-established efficacy and safety profiles.